Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hybrid Revascularization Observational Study

This study has been completed.
Sponsor:
Collaborators:
International Center for Health Outcomes and Innovation Research
Information provided by (Responsible Party):
Mount Sinai School of Medicine
ClinicalTrials.gov Identifier:
NCT01121263
First received: May 10, 2010
Last updated: February 7, 2014
Last verified: February 2014

May 10, 2010
February 7, 2014
May 2010
August 2012   (final data collection date for primary outcome measure)
Major Adverse Cardiac and Cerebrovascular Event (MACCE) [ Time Frame: Month 12 ] [ Designated as safety issue: No ]

For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:

  • Death
  • Stroke
  • Myocardial Infarction
  • Repeat Revascularization
Major Adverse Cardiac and Cerebrovascular Event (MACCE) [ Time Frame: 12 months following coronary revascularization by either HCR or PCI ] [ Designated as safety issue: No ]

For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:

  • Death
  • Stroke
  • Myocardial infarction
  • Repeat revascularization
Complete list of historical versions of study NCT01121263 on ClinicalTrials.gov Archive Site
Major Adverse Cardiac and Cerebrovascular Event (MACCE) [ Time Frame: Occurence of MACCE through the end of study up to two years ] [ Designated as safety issue: No ]

For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:

  • Death
  • Stroke
  • Myocardial infarction
  • Repeat revascularization
Major Adverse Cardiac and Cerebrovascular Event (MACCE) [ Time Frame: 18 and 21 months following coronary revascularization by either HCR or PCI ] [ Designated as safety issue: No ]

For the purposes of this study MACCE is defined as a non-weighted composite score comprised of the following components:

  • Death
  • Stroke
  • Myocardial infarction
  • Repeat revascularization
Not Provided
Not Provided
 
Hybrid Revascularization Observational Study
Hybrid Revascularization Observational Study

The purpose of the study is to get a better understanding of patients who have multi-vessel coronary artery disease (blockages in more than one vessel bringing blood to the heart) and have either Hybrid Coronary Revascularization [HCR] (combination of surgery and catheter procedures to open up clogged heart arteries) or Percutaneous Coronary Intervention [PCI] (catheter procedures to open up clogged heart arteries). Participation in the study will last up to 21 months after a patient's heart procedure(s). The study collects information about the medical care patients receive during their planned procedure(s) and how well they do following the procedure(s). No new testing or procedures will be done. Patients will receive only the tests or procedures their doctor already has planned for them. The information collected should help to plan the design of a pivotal comparative effectiveness study of hybrid revascularization.

The increasing prevalence of coronary artery disease (CAD), advances in coronary artery bypass grafting (CABG), percutaneous coronary intervention (PCI), and concomitant medical therapy, and the costs of revascularization have resulted in rising interest regarding the appropriate indications for coronary revascularization. For patients with 3-vessel disease, revascularization by CABG has recently been rated as appropriate while revascularization by PCI has been rated uncertain. Ideally, physicians would like to offer their multi-vessel CAD patients what they truly seek: a solution which provides a safe, minimally invasive treatment that does not compromise long term durability and survival. Integrating the positive features of both PCI and CABG has been the fundamental rationale of "hybrid" coronary revascularization.

Hybrid Coronary Revascularization (HCR) (the intended combination of CABG and PCI) as a scientifically validated approach would have a major healthcare impact. The ability to deliver a new therapy for CAD that provides durability, but without the obligatory trauma and prolonged recovery time characteristic of conventional CABG would be a major advance in the field of cardiovascular medicine. Candidates in whom HCR would be particularly advantageous would be several subgroups of CAD patients that are increasing in numbers: the elderly, patients with a high predicted risk of mortality and/or morbidity for CABG, deconditioned patients or patients with significant disabilities and patients in whom treatment durability is important, but a significantly invasive approach is not an option. Moreover, HCR is likely to bridge the divide in treatment philosophies and approaches that exist between cardiologists and cardiac surgeons. Collaboration rather than competition between these specialties will ultimately benefit patients, hospitals, payers and healthcare providers. The Hybrid Revascularization Observational Study is a multi-center observational study planning grant which will explore target populations for Hybrid Coronary Revascularization (HCR), their outcomes, and variations in specific ways these patients are managed, in order to inform the design of a pivotal comparative effectiveness trial of this emerging therapeutic strategy.

Given the observational nature of the study, the HCR and PCI groups' baseline characteristics and event rates are not directly comparable; rather, the results were intended to inform the design of a larger, randomized pivotal trial. The study was designed in two phases: Cohort 1, which captured demographic, angiographic, and practice patterns data for 6,669 consecutively screened patients; and Cohort 2 which captured demographic, angiographic, practice patterns, and outcome data for 298 patients who underwent either HCR or PCI with DES (90 of whom were also part of Cohort 1).

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Cohort 1 (Angiogram Review Group): All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period.

Cohort 2 (Therapeutic Intervention Group): All patients (including those from cohort 1) who meet either of the following: (a) undergo HCR with minimally invasive LIMA-LAD CABG (HCR Group) OR (b) meet the proposed anatomic and clinical eligibility criteria defined below and undergo multivessel PCI with DES (PCI Group).

Coronary Artery Disease
Not Provided
  • Angiogram Review Group
    All consecutive and consenting patients undergoing diagnostic cardiac catheterization in a 3 month period
  • Therapeutic Intervention Group
    • Cohort 2 Therapeutic Intervention Group - HCR Patients (including those from the angiogram review group) who undergo Hybrid coronary revascularization (HCR) with minimally invasive LIMA-LAD CABG, OR
    • Cohort 2 Therapeutic Intervention Group - PCI Patients (including those from the angiogram review group) who meet the proposed anatomic and clinical eligibility criteria and undergo multivessel Percutaneous Coronary Intervention with Drug Eluting Stents
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
298
August 2013
August 2012   (final data collection date for primary outcome measure)

The following criteria apply to Cohort 2 PCI patients only:

Inclusion Criteria:

  • Signed informed consent, release of medical information, and Health Insurance Portability and Accountability Act (HIPAA) documents
  • Age 18 years or older
  • Clinical indication for revascularization
  • LAD and at least one additional vessel coronary disease (> 70% stenosis) confirmed by angiogram
  • Clinical characteristics and multi-vessel disease amenable to both PCI with DES and Hybrid as adjudicated by one interventional cardiologist and one cardiac surgeon
  • Ability to tolerate and no plans to interrupt double platelet therapy for ≥ 12 months
  • Ability to tolerate to single lung ventilation in the judgment of the investigator
  • Willing to comply with all protocol required follow-up

Exclusion Criteria:

  • Previous coronary stent within:

    • 1 month prior to enrollment for bare metal stent (BMS) or
    • 6 months prior to enrollment for DES
  • Evidence of in stent restenosis of a DES or BMS
  • Previous cardiac surgery of any kind
  • Chronic total occlusion (CTO) in LAD or ≥ 2 CTOs in major coronary territories that are considered targets for revascularization
  • Left main disease ≥ 50% stenosis
  • Presence of fresh coronary thrombus
  • Need for concomitant vascular or other cardiac surgery during the index hospitalization (including, but not limited to, valve surgery, aortic resection, left ventricular aneurysm, carotid endarterectomy or stenting, etc)
  • Previous STEMI within 30 days prior to randomization
  • Previous stroke within 6 months prior to randomization
  • Previous thoracic surgery involving the left pleural space
  • Acute decompensated heart failure within 30 days prior to randomization
  • Ejection fraction < 30%
  • Creatinine clearance ≤ 50 ml/min within 24 hours prior to randomization
  • Hemodynamic instability at time of screening
  • Body mass index > 40
  • Extra-cardiac illness that is expected to limit survival to less than 3 years
  • Participation or planned participation in another investigational intervention study within 60 days prior to randomization
  • Unable to give informed consent or potential for noncompliance with the study protocol due to psychiatric illness, organic brain disease, dementia, current alcohol abuse, mental retardation, language barrier, or geographical inaccessibility;
  • Pregnancy at time of screening or intention to become pregnant
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01121263
GCO 09-0657, 1RC1HL100951
Yes
Mount Sinai School of Medicine
Mount Sinai School of Medicine
  • International Center for Health Outcomes and Innovation Research
  • National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator: John Puskas, MD, MSc, FACS, FACC Emory University
Principal Investigator: Deborah Ascheim, MD Icahn School of Medicine at Mount Sinai (Data Coordinating Center)
Principal Investigator: Joseph J DeRose, MD, FACS Montefiore Medical Center
Principal Investigator: Michael Argenziano, MD, FACS Columbia University
Principal Investigator: Mathew Williams, MD Columbia University
Principal Investigator: John G. Byrne, MD Vanderbilt University
Mount Sinai School of Medicine
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP